Richard N Channick
Overview
Explore the profile of Richard N Channick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
3576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brownstein A, Mura M, Ruffenach G, Channick R, Saggar R, Kim A, et al.
Am J Physiol Lung Cell Mol Physiol
. 2024 Aug;
327(4):L520-L534.
PMID: 39137526
Integrative multiomics can help elucidate the pathophysiology of pulmonary fibrosis (PF)-associated pulmonary hypertension (PH) (PF-PH). Weighted gene coexpression network analysis (WGCNA) was performed on a transcriptomic dataset of explanted lung...
2.
Brownstein A, Wilkinson J, Liang L, Channick R, Saggar R, Kim A
Pulm Circ
. 2024 Aug;
14(3):e12421.
PMID: 39105130
Various erythropoietic abnormalities are highly prevalent among patients with pulmonary arterial hypertension (PAH) and associated with worse disease severity. Given the poorly understood yet important roles of dysregulated erythropoiesis and...
3.
Frantz R, McLaughlin V, Sahay S, Escribano Subias P, Zolty R, Benza R, et al.
Lancet Respir Med
. 2024 May;
12(7):523-534.
PMID: 38705167
Background: Morbidity and mortality in pulmonary arterial hypertension (PAH) remain high. Activation of platelet-derived growth factor receptor, colony stimulating factor 1 receptor, and mast or stem cell growth factor receptor...
4.
Harder E, Abtin F, Nardelli P, Brownstein A, Channick R, Washko G, et al.
Am J Respir Crit Care Med
. 2024 Mar;
209(9):1170-1173.
PMID: 38502314
No abstract available.
5.
Mohr K, Keeling B, Kaier K, Neusius T, Rosovsky R, Moriarty J, et al.
Eur Heart J Acute Cardiovasc Care
. 2024 Feb;
13(6):501-505.
PMID: 38349225
Aims: Catheter-directed treatment (CDT) of acute pulmonary embolism (PE) is entering a growth phase in Europe following a steady increase in the USA in the past decade, but the potential...
6.
Winkler T, Kohli P, Kelly V, Kehl E, Witkin A, Rodriguez-Lopez J, et al.
Respir Res
. 2022 Dec;
23(1):325.
PMID: 36457013
Background: Without aggressive treatment, pulmonary arterial hypertension (PAH) has a 5-year mortality of approximately 40%. A patient's response to vasodilators at diagnosis impacts the therapeutic options and prognosis. We hypothesized...
7.
Mei J, Channick R, Afshar Y
Heart Fail Clin
. 2022 Nov;
19(1):75-87.
PMID: 36435575
Pulmonary hypertension is one of the highest risk medical conditions in pregnancy and carries significant maternal morbidity and mortality as well as neonatal morbidity. Diagnosis is commonly delayed due to...
8.
McLaughlin V, Channick R, Bell Lynum K, Oudiz R, Selej M, Tapson V, et al.
Pulm Circ
. 2022 Sep;
12(3):e12134.
PMID: 36172596
The Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative Extension Program was designed to support physicians' adherence to pulmonary arterial hypertension (PAH) guidelines. Guidelines were followed in >95% of patients with functional...
9.
Souza R, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, et al.
Adv Ther
. 2022 Jul;
39(9):4374-4390.
PMID: 35819570
Introduction: In SERAPHIN, a long-term, event-driven, double-blind randomised controlled trial in pulmonary arterial hypertension (PAH), macitentan 10 mg significantly reduced the risk of morbidity/mortality compared with placebo. Its open-label extension...
10.
Morris T, Fernandes T, Channick R
Chest
. 2022 Jul;
163(4):933-941.
PMID: 35792185
Long-term dyspnea and exercise intolerance are common clinical problems after acute pulmonary embolism. Unfortunately, no single test can distinguish among the range of potential pathologic outcomes after pulmonary embolism. We...